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Exome sequencingAbstract Background: Sulﬁte oxidase deﬁciency (SOD) is a rare neurometabolic inherited disor-
der causing severe delay in developmental stages and premature death. The disease follows an auto-
somal recessive pattern of inheritance and causes deﬁciency in the activity of sulﬁte oxidase, an
enzyme that normally catalyzes conversion of sulﬁte to sulfate.
Aim of the study: SOD is an underdiagnosed disorder and its diagnosis can be difﬁcult in young
infants as early clinical features and neuroimaging changes may imitate some common diseases.
Since the prognosis of the disease is poor, using exome sequencing as a powerful and efﬁcient strat-
egy for identifying the genes underlying rare mendelian disorders can provide important knowledge
about early diagnosis, disease mechanisms, biological pathways, and potential therapeutic targets.
Patients and methods: In this study, a case who was a newborn infant boy with suspected SOD
and his healthy parents were recruited for exome sequencing. The ﬁrst laboratory reports of the
patient were positive urine sulﬁte, elevated urinary thiosulfate, and high levels of plasma lactate
and pyruvate. The patient also presented some symptoms such as intractable seizures, abnormal
tone, feeding difﬁculties, profound mental retardation, abnormal respiratory drive, aspiration
pneumonia, microcephaly, and dislocated ocular lenses. The genomic DNA of the patient andail.com
132 M.-R. Aghanoori et al.his parents was extracted from peripheral blood lymphocytes as targets for exome sequencing,
performed by Axeq Technologies (Amsterdam, the Netherlands).
Results: The results showed no single predominate mutation in the SUOX gene as one of the
candidate genes involved in the catabolism of sulfur-containing amino acids. The same results
obtained in the molybdenum cofactor biosynthetic genes (MOCS1, MOCS2, and GEPH genes).
Instead, the results revealed that causal variations are present in genes underlying in different
biochemical pathways among which the sulfur metabolism, signaling and signal transduction,
and transcription pathways are of higher importance.
Conclusion: In this study, several classes of genes were introduced as candidate genes involved in
SOD. However, further studies are necessary to examine the reported genes in more details on how
these genes may relate to each other and contribute to the pathology of SOD disease.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sulﬁte oxidase deﬁciency (SOD) is an inherited disease which
causes neurometabolic abnormalities due to changes in
sulfated amino acid metabolism and leading to early death
[1]. Two forms of SOD are distinguished and referred to as
molybdenum cofactor deﬁciency and isolated sulﬁte oxidase
deﬁciency [2]. They have cumulatively been identiﬁed in fewer
than one hundred cases, and isolated sulﬁte oxidase deﬁciency
seems to be much less common [2,3]. Although patients with
molybdenum cofactor deﬁciency manifest xanthinuria, clinical
symptoms are similar in both forms [4]. Sulﬁte oxidase is a
soluble homo-dimer enzyme with a molecular mass of
101–110 kDa located in the inter-membrane space of mito-
chondria [5,6]. This enzyme transfers electrons from sulﬁte into
the electron transport chain by means of cytochrome c [7]. In
fact, sulﬁte oxidase is responsible for oxidizing toxic sulﬁtes to
nontoxic sulfates in the ﬁnal step of the metabolism pathway
of the sulfur amino acids including methionine and cysteine
[5]. Since sulﬁte oxidase enzyme is generally deﬁcient as a result
of a defect in a gene coding for sulﬁte oxidase or coding for its
cofactor [8], two other metabolites sulfocysteine and thiosul-
fate are formed in alternative metabolic pathways [9]. The
sulﬁte oxidase gene (SUOX) is mostly expressed in liver,
kidney, skeletal muscle, heart, placenta, and the cerebral
cortex [10]. This gene is located on chromosome 12 in the
region of q13.2, and its coding sequence contains only one
intron. The product of the gene is a protein named molybdo-
hemoprotein (sulﬁte oxidase) with 466 amino acids [3]. Its
cofactor, molybdenum, is a truncated protein normally synthe-
sized by a complex pathway that requires the products of at
least four different genes (MOCS1, MOCS2, MOCS3, and
GEPH). Based on the recent researches, causative mutations
have been identiﬁed in MOCS1, MOCS2, and GEPH, and a
total of 32 different disease-causing mutations have been
detected in molybdenum cofactor-deﬁcient patients and their
relatives [11]. As a rare disease, SOD and its genetic variants
can be investigated through new and promising technologies
such as exome sequencing (ES). ES is a powerful new tool
for gene discovery in medical genetic research [12]. The ﬁrst
study to determine if it was possible to identify causal genetic
variants using ES was carried out in 2009 for detection of the
Freeman–Sheldon Syndrome (FSS) (OMIM 193700) [13]. This
experiment helped to conﬁrm that ES can be used to identify
causal variants of rare genetic disorders, especially unknown
causal genes for rare Mendelian diseases. Therefore, ES canbe applied to locate pathogenic genes in such disorders that
previously have not been possible to study due to limitations
in traditional methods. The aim of present study was to recruit
this new method as the state-of-the-art diagnostic tool for
identifying genes involved in a patient with suspected SOD.2. Clinical report
The age of onset for SOD disorder is typically after the ﬁrst
month of life (10-week to 15-month). In this report, a 5-
month-old boy, born after a normal pregnancy and delivery
was selected as the case. The parents of this case were maternal
ﬁrst-cousins (mother age: 22 and father age: 28). Since enzy-
matic proof of diagnosis may take several months and may
require invasive studies, diagnosis of SOD was carried out
based on the presence or absence of physical ﬁndings and char-
acteristic metabolites. The ‘‘classic presentation’’ of the patient
included intractable seizures and abnormal tone (particularly
opisthotonus). Feeding difﬁculties were present shortly after
birth, and some problems including poor feeding that requires
a gastrostomy tube, vomiting, and gastroesophageal reﬂux was
observed in ﬁrst weeks of life. The infant had profound mental
retardation, abnormal respiratory drive, aspiration pneumo-
nia, microcephaly, and dislocated ocular lenses. A positive sul-
ﬁte dipstick ﬁnding of very fresh urine was highly suggestive of
SOD. An elevated urinary thiosulfate level was also essentially
diagnostic of SOD. Plasma lactate and pyruvate levels were
signiﬁcantly elevated, although these ﬁndings are nonspeciﬁc.
(Besides, other recently-reported speciﬁc chemicals like
S-sulfocysteine and xanthine were not detected in urine
[14,15]). No medical treatments that improve neurologic out-
come are known, particularly for those with neonatal presenta-
tion of SOD (except in one case with Molybdenum cofactor
deﬁciency [16]); however, this patient showed some clinical
beneﬁt from a cysteine-restricted and methionine-restricted
diet.3. Materials and methods
Genomic DNA was extracted using ZR DNA puriﬁcation kit
(Zymoresearch, USA) from the blood of the affected person
and his unaffected parents and consequently was prepared
for Illumina sequencing library performed by Axeq
Technologies (Axeq Europe, the Netherlands). Since in the
ﬁrst step of analysis, we could not conﬁrm previously reported
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were enriched for desired targets using Illumina Exome
Enrichment protocol. Subsequently, captured libraries were
sequenced using Illumina HiSeq 2000 Sequencer (Figs. 1 and 2).
4. Results
In current study, mutations in the SUOX gene and the genes
identiﬁed as the components of the molybdenum cofactor
(MOCS1, MOCS2, and GEPH genes) were found not to have
any single predominate mutation. The results obtained
through the data analysis of the mentioned case and his family
are presented in Supplementary material Table 1. This table
includes information about investigated reads, target regions
and target genotypes, as well as the number of coding SNPs,
synonymous SNPs, nonsynonymous SNPs, Indels, and coding
Indels. The application of general ﬁlter and custom ﬁlter data
analysis process provided the required information on the
studied genes. The general ﬁlter supplied knowledge on
variations, changes, regions, and SNPs. The custom ﬁlter, on
the other hand, detailed more data about different variants
causing SOD (Supplementary material Table 2). Variants
extracted by custom ﬁlter were categorized as 52 Simple
Recessive (illustrated in Table 1), 33 Compound
Heterozygote (presented in Table 2), and 118 De novo (data
are not shown). Since De novo variants were not worthwhile
to mention, only Simple Recessive and Compound
Heterozygote mutations were deeply deliberated and discussed
to explore the real causing ones in relation to SOD.Figure 1 The analysis procedu
Figure 2 Classiﬁcation procedure of d5. Discussion
Since the ﬁrst description of SOD in 1967, several cases have
been identiﬁed mostly with severe neurological abnormalities,
refractory seizures imitating hypoxic-ischemic encephalopathy,
and early death [5,17]. The identiﬁcation of SOD is somehow
dubious as it does not have a simple diagnostic test [9].
Therefore, this inherited disease could easily be missed based
on routine screening [18]. However, several molecular
investigations have been done so far, which enable accurate
diagnosis of disease. For example, in 1996 a point mutation
in SUOX was reported in an SOD patient resulting in a
truncated protein which missed the molybdenum-binding site
[19]. In 1997, four variants in the coding sequence of cloned
human sulﬁte oxidase (Arg160Gln, Ala208Asp, Ser370Tyr,
and Gly473Asp) including two point mutations near the sul-
fate binding site and two point mutations within the domain
mediating dimerization were characterized [5]. Subsequently,
in 1999, two point mutations namely 623C3A and 1109C3A
were found in SUOX gene leading to A208D and S370Y sub-
stitutions, respectively, in which both residues are critical for
sulﬁte oxidase activity [18]. Afterward, twelve novel mutations
in the SUOX gene in SOD patients were detected in 2002.
These mutations consisted of two frame-shift mutations,
a 4-basepair deletion (562del4), a 1-basepair insertion
(113insC), nonsense mutations causing Y343X and Q364X
substitutions, and eight missense mutations generating substi-
tutions of a single amino acid [3]. Additionally, a unique
4-basepair deletion in a homozygous state was detected inre of data achieved by ES.
ata analysis after implementing ES.
Table 1 Simple recessive variants identiﬁed by ES.
Chromosome Father Mother Patient Region Gene Change
Chr1:113257782 C>T het C>T hom Exonic PPM1J nonsynonymous_SNV
Chr1:120469147 T>C het T>C het T>C hom Exonic NOTCH2 nonsynonymous_SNV
Chr1:203455861 A>G het A>G het A>G hom Exonic PRELP nonsynonymous_SNV
Chr1:212981105 T>C het T>C het T>C hom Exonic TATDN3 nonsynonymous_SNV
Chr1:214507610 G>T het G>T het G>T hom Exonic SMYD2 nonsynonymous_SNV
Chr1:217975157 C>T het C>T het C>T hom Exonic SPATA17 stopgain_SNV
Chr1:231362783 G>A het G>A het G>A hom Exonic C1orf131 nonsynonymous_SNV
Chr2:166810195 ->CGCTCACC het ->CGCTCACC hom Exonic; splicing TTC21B;TTC21B frameshift_insertion
Chr2:169713209 G>A het G>A het G>A hom Exonic NOSTRIN nonsynonymous_SNV
Chr2:187559049 ->GCA het -.GCA hom Exonic FAM171B nonframeshift_insertion
Chr2:223504402 G>A het G>A het G>A hom Exonic FARSB nonsynonymous_SNV
Chr4:41015833 A>G het A>G het A>G hom Exonic APBB2 nonsynonymous_SNV
Chr5:74021853 ACTCAA>- het ACTCAA>- het ACTCAA>- hom Exonic GFM2 nonframeshift_deletion
Chr5:74032599 G>A het G>A het G>A hom Exonic GFM2 nonsynonymous_SNV
Chr5:79616278 A>G het A>G het A>G hom Exonic SPZ1 nonsynonymous_SNV
Chr5:139931628 ->GT het ->GT het ->GT hom Exonic SRA1 frameshift_insertion
Chr6:99323489 ->GA het ->GA het ->GA hom Exonic FBXL4 frameshift_insertion
Chr7:100637839 C>G het C>G het C>G hom Exonic MUC12 nonsynonymous_SNV
Chr7:100645525 A>C het A>C hom Exonic MUC12 nonsynonymous_SNV
Chr7:131241054 ->GCGA CG het ->GCGACG hom Exonic PODXL nonframeshift_insertion
Chr7:143417083 T>C het T>C het T>C hom Exonic FAM115C nonsynonymous_SNV
Chr7:158664076 AAG>- het AAG>- het AAG>- hom Exonic WDR60 nonframeshift_deletion
Chr8:18257703 C>T het C>T het C>T hom Exonic NAT2 nonsynonymous_SNV
Chr9:103340627 G>A het G>A het G>A hom Exonic MURC nonsynonymous_SNV
Chr9:107367666 CG>- het CG>- het CG>- hom Exonic OR13C2 frameshift_deletion
Chr10:124352012 C>T het C>T het C>T hom Exonic DMBT1 nonsynonymous_SNV
Chr11:124750455 GGAGTC>- het GGAGTC>- hom Exonic ROBO3 nonframeshift_deletion
Chr12:6777111 CTG>- het CTG>- het CTG>- hom Exonic ZNF384 nonframeshift_deletion
Chr12:102131655 T>C het T>C het T>C hom Exonic SYCP3 nonsynonymous_SNV
Chr12:102160048 A>G het A>G het A>G hom Exonic GNPTAB nonsynonymous_SNV
Chr12:103248932 C>T het C>T het C>T hom Exonic PAH nonsynonymous_SNV
Chr12:107155117 C>T het C>T het C>T hom Exonic RFX4 nonsynonymous_SNV
Chr12:110206380 G>A het G>A het G>A hom Exonic C12orf34 nonsynonymous_SNV
Chr12:113346579 A>C het A>C het A>C hom Exonic; splicing OAS1 nonsynonymous_SNV
Chr12:123214166 G>A het G>A het G>A hom Exonic HCAR1 nonsynonymous_SNV
Chr12:123351773 G>A het G>A het G>>A hom Exonic VPS37B nonsynonymous_SNV
Chr12:129100757 C>G het C>G het C>G hom Exonic TMEM132C nonsynonymous_SNV
Chr14:23240726 ->GCA het ->GCA het ->GCA hom Exonic OXA1L nonframeshift_insertion
Chr14:23548797 ->ACGTGA het ->ACGTGA het ->ACGTGA hom Exonic ACIN1 nonframeshift_insertion
Chr15:21071460 C>T het C>T hom Exonic POTEB nonsynonymous_SNV
Chr15:82637110 C>T het C>T hom Exonic GOLGA6L10 nonsynonymous_SNV
Chr16:71981420 ->TGTT het ->TGTT hom Exonic PKD1L3 unknown
Chr16:81242150 TT>- het TT>- het TT>- hom Exonic PKD1L2 frameshift_deletion
Chr17:18064722 C>T het C>T het C>T hom Exonic MYO15A nonsynonymous_SNV
Chr17:19566768 C>T het C>T het C>T hom Exonic ALDH3A2 nonsynonymous_SNV
Chr17:29226507 C>T het C>T het C>T hom Exonic TEFM nonsynonymous_SNV
Chr19:52803674 TG>- het TG>- het TG>- hom Exonic ZNF480 frameshift_deletion
ChrX:70367609 C>T het C>T hom Exonic NLGN3 nonsynonymous_SNV
ChrX:114424132 G>A het G>A hom Exonic RBMXL3 nonsynonymous_SNV
ChrX:135474448 GAT>- het GAT>- hom Exonic GPR112 nonframeshift_deletion
ChrX:149680832 C>T het C>T hom Exonic MAMLD1 nonsynonymous_SNV
ChrX:151935412 T>C het T>C hom Exonic MAGEA3 nonsynonymous_SNV
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[20]. In 2005, mutation analysis of SUOX showed a novel
4-basepair deletion in a patient whose parents were found to
be heterozygous carriers of the deletion [1]. In other studies,
a homozygous nonsense mutation of the SUOX gene in the
patient was identiﬁed by a genome wide microarray analysis
[21]. The present study was actually a breakthrough indiagnosis of a variety of genetic elements involved in the
pathogenesis of SOD (a patient with suspected SOD) because
of applying ES as a useful tool for detecting disease-causing
mutations. Although we did not ﬁnd any mutations in
SUOX, MOCS1, MOCS2, and GEPH genes, the child was
conﬁrmed to be an SOD case because of having biochemical
and clinical signs of the disease. Thus, other genetic variants
Table 2 Compound Heterozygote variants identiﬁed by ES.
Chromosome Father Mother Patient Region Gene Change
Chr1:161967990 G>A het G>A het Exonic OLFML2B nonsynonymous_SNV
Chr2:161970046 A>G het A>G het Exonic OLFML2B nonsynonymous_SNV
Chr1:170129665 T>G het T>G het Exonic METTL11B nonsynonymous_SNV
Chr1:170136876 T>C het T>C het Exonic METTL11B nonsynonymous_SNV
Chr3:19389225 T>A het Exonic KCNH8 nonsynonymous_SNV
Chr3:19559510 G>C het G>C het Exonic KCNH8 nonsynonymous_SNV
Chr4:8951859 G>A hom G>A het Exonic LOC650293 Stopgain_SNV
Chr4:8951918 C>T het C>T het Exonic LOC650293 nonsynonymous_SNV
Chr8:2005572 G>A het G>A het Exonic MYOM2 nonsynonymous_SNV
Chr8:2020542 C>T het C>T het Exonic MYOM2 nonsynonymous_SNV
Chr8:110455184 C>T het Exonic PKHD1L1 nonsynonymous_SNV
Chr8:110492352 C>T het C>T het C>T het Exonic PKHD1L1 nonsynonymous_SNV
Chr10:76735758 G>A het G>A het Exonic KAT6B nonsynonymous_SNV
Chr10:76781927 GAA>- het Exonic KAT6B nonframeshift_deletion
Chr11:66359172 C>T het C>T het Exonic CCDC87 nonsynonymous_SNV
Chr11:66360206 C>T het C>T het Exonic CCDC87 nonsynonymous_SNV
Chr11:89819403 G>C het Exonic UBTFL1 nonsynonymous_SNV
Chr11:89819889 ->T het ->T het Exonic UBTFL1 frameshift_insertion
Chr12:112688164 T>C het Exonic C12orf51 nonsynonymous_SNV
Chr12:112688167 A>C het A>C het Exonic C12orf51 nonsynonymous_SNV
Chr16:72821644 C>T het Exonic ZFHX3 nonsynonymous_SNV
Chr16:72822581 CTGCTG>- het CTGCTG>- het CTGCTG>- het Exonic ZFHX3 nonframeshift_deletion
Chr18:14105193 C>T het C>T het Exonic ZNF519 nonsynonymous_SNV
Chr18:14106282 T>G het T>G het Exonic ZNF519 nonsynonymous_SNV
Chr18:28972226 C>A het C>A het Exonic DSG4 nonsynonymous_SNV
Chr18:28993231 T>G het T>G het Exonic DSG4 nonsynonymous_SNV
Chr19:40900200 CTC>- het Exonic PRX nonframeshift_deletion
Chr19:40901647 A>G het Exonic PRX nonsynonymous_SNV
Chr19:40902713 G>A het G>A het Exonic PRX nonsynonymous_SNV
Chr19:42596244 C>A het C>A het Exonic POU2F2 nonsynonymous_SNV
Chr19:42596347 G>T het Exonic POU2F2 nonsynonymous_SNV
Chr19:51960988 T>A het T>A het Exonic SIGLEC8 nonsynonymous_SNV
Chr19:51961638 GCA>- het Exonic SIGLEC8 nonframeshift_deletion
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to our suspected SOD case. The results obtained in this study
showed that the variations can be classiﬁed via the custom ﬁl-
ter to different genes groups partaking in about 10 pathways
among which the sulfur metabolism (e.g. DMBT1, PRELP,
and PAH), signaling and signal transduction (e.g. MUC12,
MURC, HCAR1, NLGN3, ROBO3, ZFHX3, APBB2, SPZ1,
SRA1, andWDR60), membrane and trans-membrane proteins
(e.g. FAM171B, NOTCH2, GPR112, HCAR1, MYO15A,
PKD1L2, TMEM132C, PRX, PKD1L3, and ROBO3), and
transcription (e.g. MAMLD1, RBMXL3, RFX4, ZNF384,
ZNF480, KAT6B, POU2F2, PRX, ZFHX3, ZNF519, TEFM,
and SPZ1) pathways are of higher importance (www.kegg.jp,
www.genecards.org). The results conﬁrmed that there are some
genes more correlated than the others to the sulfur metabolism
and sulfur relay system pathways and SOD disease, and prob-
ably they can be considered as candidate genes underlying
manifestation of SOD symptoms. Among them, DMBT1 and
PRELP in sulfur metabolism pathway, and MUC12,
MURC, HCAR1, NLGN3, ROBO3, SPZ1, and SRA1 in
signaling and signal transduction pathways can be candidate
genes in succeeding molecular diagnostic tests. However,
future studies are necessary to examine how these genes may
relate to each other and contribute to the pathogenesis of
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